menu toggle
Friday, November 28
Our offices will also be closed on Friday, November 28. While some deliveries will take place on Friday according to network operations, our Customer Service and Customer Systems Support teams will be unavailable. Please review our full holiday schedule for more detailed information and to plan your orders accordingly.
Action required: New logo and email address for invoices starting October 18
Ensure that you’re prepared to continue receiving invoices electronically.

February 1, 2022

Now available PEMFEXY™ (pemetrexed injection)

PEMFEXY ™ (pemetrexed injection) is a folate analog metabolic inhibitor indicated for:

  • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC). (1.1)

  • as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (1.1)

  • as a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy. (1.1) Limitations of Use: PEMFEXY is not indicated for the treatment of patients with squamous cell non-small cell lung cancer. (1.1)

  • in combination with cisplatin for the initial treatment, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. (1.2)

 

 

Please see the full prescribing information.